UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play
In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy rating and $35.00 price target.
In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $35. Epizyme is a pure-play on epigenetics, a gene regulatory system that can be exploited to target cancer cells. While the company's pipeline is early phase, valuation is supported by a series of significant biopharmaceutical partners, a series of 4Q14 Phase I readouts, and a platform and IP for further discovery.”
Epizyme closed on Thursday at $28.20.
Latest Ratings for EPZM
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | HC Wainwright & Co. | Maintains | Buy | |
Aug 2021 | Morgan Stanley | Downgrades | Equal-Weight | Underweight |
Aug 2021 | HC Wainwright & Co. | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Mizuho Securities USA Peter LawsonAnalyst Color Initiation Analyst Ratings